madinamerica
Justin Karter 10/10/2018
This week, we present the first in a series of interviews on the topic of the global ‘mental health’ movement. These interviews will be led by our Mad in America research news team.
[Ed; at the link. Listen to interview]
In this episode, we interview Dr. Melissa Raven, who is a psychiatric epidemiologist, policy analyst and postdoctoral research fellow in the Critical and Ethical Mental Health research group at the University of Adelaide, South Australia. Originally qualified as a clinical psychologist, she then worked as a lecturer and researcher in public health and primary health care. Her current mental health research and advocacy is informed by a strong social determinants perspective and a strong critical orientation, which she applies to a range of topics, including suicide prevention, workplace mental health, (over)diagnosis, (inappropriate) prescribing, and conflicts of interest in mental health and the broader health/welfare arena.
On October 10th, 2018, World Mental Health Day, The Lancet Commission on Global Mental Health and Sustainable Development published a report outlining a proposal to “scale up” mental health care globally. At the same time, the UK government is hosting a Global Mental Health Ministerial Summit with the intention of laying out a course of action to implement these mental health policies globally.
In response, a coalition of mental health activists and service-users have organized an open letter detailing their concerns with the summit and report. The response has attracted the support of critical professionals, psychologists, psychiatrists, and researchers.
Thank You Mr Karter and MIA.
Showing posts with label Psych Headline News Links/MIA. Show all posts
Showing posts with label Psych Headline News Links/MIA. Show all posts
Wednesday, October 10, 2018
Tuesday, September 22, 2015
Psych Headline News Links 9-22-2015
Can Anyone tell us WHY we keep breaking the Treasury's back to feed this industry?
"Because HOPE Remains For A Cure?"
Remember the last time we made policy based on HOPE?
Real Unemployment Rate 42.9%, Not 5.5%
White House Blocks Petition Seeking Investigation Into Psychiatric Drugs And Violence
A Message From President Obama About Your Petition On Reducing Gun Violence
J&J/PhARMA Parented ObamaCare
Barf Alert! Obama Consults J&J CEO Weldon On Fixing The Economy
madinamerica
"Because HOPE Remains For A Cure?"
Remember the last time we made policy based on HOPE?
Real Unemployment Rate 42.9%, Not 5.5%
White House Blocks Petition Seeking Investigation Into Psychiatric Drugs And Violence
A Message From President Obama About Your Petition On Reducing Gun Violence
J&J/PhARMA Parented ObamaCare
Barf Alert! Obama Consults J&J CEO Weldon On Fixing The Economy
madinamerica
September 17, 2015
On Tuesday, the Obama
administration nominated Dr. Robert Califf to be the new commissioner of the
Food and Drug Administration (FDA). In a statement, director
of the Public Citizen’s Health Research Group, Dr. Michael Carome called on the
Senate to reject the nomination. He contends that Califf “racked up a
long history of extensive financial ties to multiple drug and medical device
companies, including Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson,
Merck Sharp & Dohme and Sanofi-Aventis, to name a few.”
Categorized
In:
September 17, 2015
Individuals
between the ages of 15 and 24 are more likely to commit a violent crime if they
are taking an SSRI antidepressant than if they are not, according to new
research out of Sweden. The study published in PLoS Medicine on Tuesday,
suggests "warnings about the increased risk of violent behavior among
young people taking SSRIs might be needed.”
Categorized
In:
Adult | Adverse
Effects | Antidepressants | Children
and Adolescents | Depression | Depression | Disorders | Drug Page | Featured News | In the News | In the News | Informed
Consent | Issues | Legislation
& Regulation | Off-label | Psychiatric | Psychiatric
Drugs | Suicidality/Homicidality | Violence
September 16, 2015
BMJ issued
a press release today
after a reanalysis of the antidepressant paroxetine (Paxil) concluded the drug
is neither safe nor effective for adolescents with depression. The reanalysis
conducted by a team of independent researchers contradicts the original study
paid for by the drug manufacturer, known as Study 329.
Categorized
In:
September 16, 2015
After
13 years as the director of the National Institute of Mental Health (NIMH), Dr.
Thomas Insel is stepping down. While the NIMH conducts a national search
for his replacement, Bruce Cuthbert, Ph.D., will serve as the acting director.
Categorized
In:
September 16, 2015
New research published in
the August issue of Psychiatric Annals evaluates
the results of randomized control trials on the use of various psychotropic
drugs for patients diagnosed with borderline personality disorder (BPD).
Despite the “American Psychiatric Association’s practice guidelines
endorsement of SSRIs as first-line therapies for BPD,” the results of the
meta-analysis reveal that pharmacotherapy in BPD is “not supported by the
current literature,” and “should be avoided whenever possible.”
Categorized
In:
Adult | Antidepressants | Antipsychotics | Disorders | Featured News | In the News | Mood
Stabilizers | Off-label | Personality
Disorders | Psychiatric
Drugs | Psychotherapy |Research
September 14, 2015
“In
Gallup's annual measure of 25 major U.S. business sectors, the percentage of
Americans with a positive view of the pharmaceutical industry dropped from 40%
in 2014 to 35% this year, while the percentage with a negative view rose from
36% to 43%.”
Categorized
In:
Adverse
Effects | Featured News | Globalization | In the News | Issues | Legislation
& Regulation | Media | Privacy
& Surveillance | Psychiatric
Drugs | Seniors | Stigma
& Bigotry |Suicide | Violence | Workplace
September 11, 2015
New
data on the effects of social support after the onset of psychosis suggests
that patients with intense social support function better than those without
such help, but than once supports are removed the effects eventually diminish.
Categorized
In:
Adult | Antipsychotics | Children
and Adolescents | Community | Disorders | Early
Intervention | Featured News | Hearing
Voices | In the News | Non-drug
Approaches | Peer Support| Recovery/Empowerment | Schizophrenia
and Psychosis | Schizophrenia
and Psychosis
September 10, 2015
Amid growing criticism
about the over-prescription of psychotropic medication in foster care,
Pennsylvania commissioned PolicyLab to
conduct an analysis of the use of psychiatric drugs among all of the state’s
Medicaid-enrolled children. The report, released in June, found that the
rates of psychotropic prescriptions among youth in Medicaid and foster care are
higher than previous estimates.
Categorized
In:
ADHD | Adverse
Effects | Antipsychotics | Causation
Theories | Childhood
Adversity/Trauma | Children
and Adolescents | Drug Page | Featured News | In the News | In the News |Issues | Legislation
& Regulation | Off-label | Over-diagnosis | Poverty | Psychiatric
Drugs | Trauma/Distress
September 9, 2015
Antipsychotics
are currently the predominant treatment for individuals diagnosed with
schizophrenia, but there is an accumulating body of research that links the use
of these drugs to structural abnormalities in the brain. A recent meta-analysis
suggests that gray matter loss in the brain may depend on the dose and class of
the antipsychotic.
Categorized
In:
Adult | Adverse
Effects | Antipsychotics | Children
and Adolescents | Disorders | Drug Page | Featured News | In the News | In the News | Psychiatric | Psychiatric
Drugs | Research |Schizophrenia
and Psychosis | Schizophrenia
and Psychosis
September 8, 2015
Antipsychotics are being
prescribed to people who may have challenging behaviors but no mental disorder,
according to new research published in this month’s issue of BMJ.
In people without intellectual disability, approximately 50% of
prescriptions for antipsychotics are given in the absence of a diagnosis of
severe mental illness. According to the new analysis, an even
higher proportion (71%) of those with intellectual disabilities receive
antipsychotics without such a diagnosis.
Categorized
In:
Adverse
Effects | Antipsychotics | Bias, Corruption & Accountability | Drug Page | Featured News | In the News | In the News | Informed
Consent | Legislation
& Regulation |Obesity/Metabolic
Syndrome | Over-diagnosis | Psychiatric | Psychiatric
Drugs | Research | Stigma
& Bigotry
September 7, 2015
This month’s issue of JAMA
Psychiatry ran an editorial commenting on recent research revealing
that the majority of youth prescribed antipsychotics have not been diagnosed
with a mental disorder. For these youth, the harms outweigh the benefits.
Categorized
In:
ADHD | Adverse
Effects | Anxiety | Autism | Bipolar | Causation
Theories | Childhood
Adversity/Trauma | Children
and Adolescents | Depression | Drug Page | Early
Intervention |Featured News | In the News | In the News | Issues | Legislation
& Regulation | Obesity/Metabolic
Syndrome | Off-label | Over-diagnosis | Psychiatric
Drugs | Research |Schizophrenia
and Psychosis | Substance
Abuse/Addiction
September 4, 2015
In the September issue of The
Journal of the American Medical Association (JAMA) three
FDA advisory committee members describe the convergence of factors that made
the committee’s recommendation to approve flibanserin especially challenging
and politically charged. The authors of the JAMA editorial,
Walid Gellad, Kathryn Flynn, and Caleb Alexander, all served on the FDA
scientific advisory committee that ultimately recommended approval of
flibanserin for the treatment of hypoactive sexual desire disorder
(HSDD). They list all of the following factors as explanations for what
made the committee’s decision so difficult in this case, but do not offer a
thorough explanation as to why the drug was ultimately approved despite these
issues.
Categorized
In:
Adverse
Effects | Antidepressants | Bias, Corruption & Accountability | Depression | Disorders | Drug Page | Featured News | In the News | In the News | Industry | Issues | Legislation
& Regulation | Off-label | Over-diagnosis | Placebos | Psychiatric
Drugs | Research | Upon
Further Review
September 2, 2015
MedPageToday reports
that Janssen Pharmaceuticals omitted data from a 2003 study that connected
Risperdal with serious side effects. Earlier this year, a man with autism was
awarded $2.5 million after growing breasts while on Risperdal. According
to MedPage, documents from this latest case reveal missing data tables
from a 2003 study “designed to ferret out potential adverse effects of
long-term risperidone use.” The missing tables were related to elevated
prolactin levels and side effects, including gynecomastia in men.
Categorized
In:
Adverse
Effects | Antipsychotics | Autism | Bias, Corruption & Accountability | Children
and Adolescents | Featured News | In the News | Industry | Issues | Legislation
& Regulation |Obesity/Metabolic
Syndrome | Psychiatric
Drugs | Research
August 31, 2015
Bertha Madras, professor
of psychobiology at Harvard Medical School, has printed a critique listing 20
flaws to a recent study finding no differences in physical or mental health
problems between users and non-users of marijuana. More →
Categorized
In:
Adverse
Effects | Children
and Adolescents | Featured News | In the News | Popular | Research | Substance
Abuse/Addiction | Substance
Abuse/Addiction
August 27, 2015
Willingness to interact
with someone with a mental health diagnosis may be tied to the misperception
that disorders can be transferred from one person to another, according to a
new study published in the Journal of Memory & Cognition.More →
Categorized
In:
ADHD | Adult | Anorexia | Anxiety | Bipolar | Dementia | Depression | Disorders | Featured News | Hearing
Voices | In the News | Issues | Peer Support | Personality
Disorders | PTSD| Schizophrenia
and Psychosis | Stigma
& Bigotry | Substance
Abuse/Addiction
August 26, 2015
Despite updated standards
requiring preregistration of clinical trials aimed at improving transparency,
most studies published in the top-5 psychiatry journals from 2009 to 2013 do
not meet the new guidelines, according to an analysis published in PloS
one.More →
Categorized
In:
Bias, Corruption & Accountability | Featured News | In the News | Industry | Issues | Legislation
& Regulation | Research
August 25, 2015
The combined use of
antidepressants and non-steroidal anti-inflammatory drugs (NSAIDs) is
associated with an increased risk of intracranial hemorrhage, according to a
study published last week in BMJ. More →
Categorized
In:
August 25, 2015
A study carried out by BC
Children’s Hospital in Vancouver found a 47% increase in the number of
pediatric emergency department (PED) visits related to mental health between
2003 and 2012. This staggering increase compared to a 9% increase in
total PED visits. More →
Categorized
In:
August 21, 2015
A study published in the
journal of Psychiatry Research found that younger
childhood age relative to one's classmates may be a risk factor for adult
psychotic experiences. This research supports claims that environmental
factors such as school-related difficulties and marginalization contribute to
psychosis.More →
Categorized
In:
Children
and Adolescents | Early
Intervention | Featured News | Hearing
Voices | In the News | Schizophrenia
and Psychosis | Schizophrenia
and Psychosis
August 19, 2015
On Tuesday, the U.S. Food
and Drug Administration (FDA) approved Flibanserin (Addyi) to treat low
sexual desire in women despite concerns about the drug's limited efficacy and
doubts over its clinical relevance. That the drug is being called the "pink
Viagra" can be misleading as Viagra treats erectile dysfunction by
improving blood flow while Flibanserin targets the brain, and must be taken
daily.
Categorized
In:
August 19, 2015
“When people with
early-stage symptoms took omega-3 supplements for three months, they had much
lower rates of progression than those who did not,” according to research out
of Australia covered in this month’s issue of the New
Scientist. More →
Categorized
In:
Antipsychotics | Early
Intervention | Featured News | In the News | Non-drug
Approaches | Research | Schizophrenia
and Psychosis | Schizophrenia
and Psychosis
August 17, 2015
While current treatment guidelines for
obsessive-compulsive disorder (OCD) do not recommend electroconvulsive therapy
(ECT), the NIMH is
supporting new research into
the use of ECT and deep brain stimulation (DBS) for OCD treatment.
Leonardo Fontenelle and his colleagues at the Federal University of Rio de
Janeiro in Brazil set out to examine studies on ECT treatment for OCD and found
the existing research to be too limited and inconclusive.More →
Categorized
In:
August 17, 2015
The Minnesota State
Legislature approved $1 million in funding through 2019 to build a network of
community clinics and outreach programs that provide therapy, support and
treatment to individuals experiencing an initial presentation of symptoms
associated with psychosis. The first $260,000 of funding will be
distributed through grants over the next two years. The new programs will
be modeled after the University at Minnesota’s first episode psychosis program,
which has pioneered efforts to incorporate family education and training into
therapy focused treatment programs.
Categorized
In:
Early
Intervention | Featured News | In the News | Schizophrenia
and Psychosis | Schizophrenia
and Psychosis
August 12, 2015
Seniors are twice as likely to
receive psychotropic prescriptions than younger adults but are much less likely
to receive mental health care from psychiatrists or to receive psychotherapy,
according to a recent study published in the Journal of the American
Geriatrics Society. More →
Categorized
In:
August 11, 2015
A long-term study that
followed 408 seventh-graders for over 20 years found no association between
marijuana use at a young age and an increased risk of psychosis, depression,
and anxiety in adulthood. The study, published in the journal Psychology
of Addictive Behaviors, was led by Jordan Bechtold of the University
of Pittsburgh School of Medicine.More →
Categorized
In:
August 7, 2015
The
Federal jury hearing the first of 5000 claims against Eli Lilly for
hiding the risks of withdrawal symptoms associated with Cymbalta found
that Lilly did not mislabel the drug, and was not liable for Herrera's
withdrawal symptoms.
Categorized
In:
August 7, 2015
Calling it “Poison,” plaintiff Claudia Herrera testified
she would not have taken Eli Lilly's drug Cymbalta had she known the
risks. Lilly hid the risks of withdrawal symptoms such as electric-like
“zaps,” anxiety, spasms, and suicidal ideation, Herrera lawsuit claims,
alleging that nearly half of users experience withdrawal rather than the 1%
Lilly claims.
More →
More →
Categorized
In:
August 3, 2015
The
majority of children, adolescents and young adults prescribed antipsychotic
medications have not been diagnosed with a mental disorder, according to a
recent study published in JAMA Psychiatry. The study, led by
Mark Olfson from Columbia University, examined trends in the treatment of young
people with antipsychotics in the United States between 2006 and 2010 and
raised concerns about the safety and efficacy of prescription practices.
Categorized
In:
ADHD | Antipsychotics | Children
and Adolescents | Depression | Featured News | In the News | Off-label | Psychotherapy
July 30, 2015
Research published in the
May 2015 issue of The American Journal of Psychiatry questions
the use of exposure therapy, the "gold standard" treatment for
patients with PTSD. Exposure therapy attempts to lessen the power of
memories, thoughts, and feelings related to the trauma through the repeated
discussion of the trauma-related situations with a therapist. While prior
studies have reported that it is efficacious, exposure therapy has
also been called the “cruelest cure” and
criticized for inducing suffering in victims of trauma.
Categorized
In:
July 30, 2015
Research lead by
Richard Bentall of the University of Liverpool finds that the quality of the
therapeutic alliance (TA) in treating early psychosis, long known to be
instrumental in achieving positive outcomes, can also lead to
poorer outcomes when the quality is negative. "This is the first ever
demonstration that TA has a causal effect
on symptomatic outcome of a psychological treatment, and that poor TA is
actively detrimental, these effects may extend to other therapeutic modalities
and disorders," the authors conclude.
Categorized
In:
Thank You MIA.
Subscribe to:
Posts (Atom)